Obesity Clinical Trial
— BREAKOfficial title:
Effects of Intermittent Versus Continuous Energy Restriction on Metabolic Adaptation in Women With Obesity
Verified date | December 2023 |
Source | Universidade do Porto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
One of the major challenges for treating obesity is to maintain a weight reduced state on the long term due to the high rate of weight regain. Therefore, the aim of this study is to evaluate the effects of an intermittent versus a continuous energy restriction in body composition (body weight, fat mass and fat-free mass) and metabolic adaptation, in women with obesity.
Status | Active, not recruiting |
Enrollment | 74 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: - Women - BMI ranging between 30 and 39.9 kg/m2 - Age between 20-45 years - Weight stable in the last 6 months (less than 5% weigh variation) - Inactive (less then 150 min/week of moderate physical activity or 75 min/week of vigorous physical activity - Living in Lisbon Metropolitan Area and being able to drive to Faculty of Human Kinetics and Germano de Sousa Laboratory (Algés) - Available to be randomized to any of the trial groups (CER or IER) - Willing to commit with the assigned group protocol, including the nutritional intervention and lifestyle recommendations, as well as being available for participation in all evaluation moments. Exclusion Criteria: - Previous or present health disorders: cancer, autoimmune, cardiac, psychiatric, kidney and liver disease (except liver steatosis), diabetes, chronic intestinal inflammatory disease, or other medical conditions known to affect energy balance homeostasis - Menopause - Hormonal or thyroid disorder - Medications that promote weight gain or alter energy balance, including corticosteroids, antidepressants, anxiolytics, mood-stabilizing, and antipsychotics - Medications or dietary supplements for weight-loss in the past 3 months - Pregnant for the past 6 months or breastfeeding - Planning to get pregnant in the next 2 years or getting pregnant during the study - Current consumption of more than 14 alcoholic drinks per week or other substance abuse, and/or current acute treatment or rehabilitation program for alcohol/substance abuse - Surgery or in hospital admission for the last month - Positive for Covid-19 in the past 3 months or testing positive during the intervention phase of the study |
Country | Name | City | State |
---|---|---|---|
Portugal | Faculdade de Motricidade Humana da Universidade de Lisboa | Cruz Quebrada | Lisbon |
Lead Sponsor | Collaborator |
---|---|
Universidade do Porto | University of Lisbon |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fat mass | To estimate total fat mass (FM), dual energy X-ray absorptiometry (Hologic Explorer-W, Waltham, USA) will be used. A whole-body scan will be performed and the attenuation of X-rays pulsed between 70 and 140 kV synchronously with the line frequency for each pixel of the scanned image will be measured. | 24 months | |
Primary | Adaptive thermogenesis (AT) | AT will be assessed as: AT (kcal/d) = (pREE at the end of the intervention - mREE at the end of the intervention) - (pREE baseline - mREE baseline) | 24 months | |
Secondary | Weight | Weight will be determined using a digital scale, with 0,1 kg interval (Seca, Hamburg, Germany). | 24 months | |
Secondary | Height | Height will be determined using a stadiometer Seca 704 s, with 0,1 cm intervals (Seca, Hamburg, Germany) | Baseline | |
Secondary | Body mass index (BMI) | BMI will be calculated using the formula [weight (kg)/height2(m2)] | 24 months | |
Secondary | Fat-free mass (FFM) | To estimate fat-free mass (FFM), dual energy X-ray absorptiometry (Hologic Explorer-W, Waltham, USA) will be used. A whole-body scan will be performed and the attenuation of X-rays pulsed between 70 and 140 kV synchronously with the line frequency for each pixel of the scanned image will be measured. | 24 months | |
Secondary | Resting energy expenditure (REE) | REE will be determined using indirect calorimetry COSMED Fitmate device (Cosmed, Rome, Italy) will be used to measure breath-by-breath oxygen consumption (V?O2 ) and carbon dioxide production (V?CO2) using a facial mask. | 24 months | |
Secondary | Energy balance (EB) | The EB will be calculated as: EB (kcal/d) = 1.0 * (?FMM/?t) + 9.5 * (?FM/?t). ?FM and ?FFM represent the change in grams of FM and FFM from the beginning to end of the intervention and ?t is the time length of the intervention in days. | 24 months | |
Secondary | Free-living physical activity | The amount of activity assessed by the Actigraph accelerometer will be expressed as minutes per day spent in different intensities. The cutoff values used to define the intensity of PA and therefore to quantify the mean time in each intensity (sedentary, light, moderate or vigorous) will be: sedentary: < 100 counts·min-1; light: 100-2019 counts·min-1; moderate: 2020-5998 counts·min-1 (corresponding to 3-5.9 METs); vigorous: = 5999 counts·min-1 (corresponding to =6 METs). A valid day will be defined as having 600 or more minutes (=10h) of monitor wear during waking hours. | 24 months | |
Secondary | Total daily energy expenditure (TDEE) | TDEE will be assessed by the Actigraph accelerometer using the Crouter et al equations. | 24 months | |
Secondary | Physical activity energy expenditure (PAEE) | PAEE will be calculated as total energy expenditure (TEE) minus (0.1*TEE + REE), assuming the thermic effect of food represents 10% of TEE, and REE represents Resting energy expenditure. | 24 months | |
Secondary | Blood thyroid levels | Free T3 and free T4 will be run by immunoassay with chemiluminescent detection (Advia Centaur, Siemens). | 24 months | |
Secondary | Blood insulin levels | Blood insulin levels assessment will be performed in an automated analyser with chemiluminescent detection [Advia Centaur, Siemens]. | 24 months | |
Secondary | Blood leptin levels | Serum levels of leptin will be measured by enzyme immunoassay [ELISA]. | 24 months | |
Secondary | Blood cortisol levels | Blood levels of cortisol will be determined by immunoassay with chemiluminescence detection [Advia Centaur, Siemens]. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |